OverviewSuggest Edit

Wave Life Sciences is a clinical stage genetic medicine company. The Company is utilizing its synthetic chemistry platform to design and develop nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, with a goal of delivering new and exceptional treatment options for patients. Wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi, potentially enabling it to address a broad range of therapeutic areas and diseases.

TypePublic
Founded2012
HQCambridge, US
Websitewavelifesciences.com
Employee Ratings4.4

Latest Updates

Employees (est.) (Dec 2018)250(+49%)
Job Openings19
Revenue (FY, 2018)$14.4 M(+290%)
Share Price (Jan 2020)$7.8 (-3%)

Key People/Management at Wave Life Sciences

Paul Bolno

Paul Bolno

President and Chief Executive Officer, Wave Life Sciences
Chandra Vargeese

Chandra Vargeese

Senior Vice President, Drug Discovery
Chris Francis

Chris Francis

Senior Vice President, Corporate Development, Head of Emerging Areas
Kyle Moran

Kyle Moran

Senior Vice President of Supply Chain and Operations
Wendy Erler

Wendy Erler

Vice President, Patient Advocacy and Market Insights
Show more

Wave Life Sciences Office Locations

Wave Life Sciences has offices in Cambridge, Lexington, Dublin 1, Kagoshima and in 2 other locations
Cambridge, US (HQ)
733 Concord Ave
Lexington, US
115 Hartwell Ave
Dublin 1, IE
1 Spencer Dock, Northside
Singapore, SG
7 Straits View
London, GB
Hay’s Galleria, 1 Hay's Ln
Show all (6)

Wave Life Sciences Financials and Metrics

Wave Life Sciences Revenue

Wave Life Sciences's revenue was reported to be $14.41 m in FY, 2018
USD

Revenue (Q3, 2019)

2.9m

Net income (Q3, 2019)

(50.7m)

EBIT (Q3, 2019)

(54.2m)

Market capitalization (22-Jan-2020)

266.4m

Closing stock price (22-Jan-2020)

7.8

Cash (30-Sept-2019)

209.0m

EV

87.6m
Wave Life Sciences's current market capitalization is $266.4 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Revenue

152.0k1.5m3.7m14.4m

Revenue growth, %

877%

General and administrative expense

10.4m16.0m27.0m39.5m

R&D expense

9.1m40.8m79.3m134.4m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

417.0k392.0k676.0k676.0k676.0k1.4m4.9m4.5m3.0m7.6m2.9m

General and administrative expense

2.9m3.2m3.7m3.9m5.9m6.7m7.6m8.0m8.9m9.8m10.9m11.6m12.5m

R&D expense

2.1m4.7m8.4m13.7m14.7m19.1m20.1m29.2m32.5m32.9m40.1m41.6m44.6m

Operating expense total

5.0m8.0m12.1m17.6m20.6m25.8m27.7m37.2m41.5m42.7m51.0m53.2m57.1m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

161.2m150.3m142.5m174.8m

Accounts Receivable

200.0k10.0m

Prepaid Expenses

8.0m17.5m

Inventories

146.0k1.5m
Quarterly
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(19.2m)(55.4m)(102.0m)(146.7m)

Depreciation and Amortization

594.0k784.0k2.2m5.6m

Inventories

(63.0k)(1.3m)

Accounts Payable

1.6m3.4m3.9m4.9m
USDY, 2019

EV/EBIT

-1.6 x

EV/CFO

-0.7 x

Financial Leverage

3 x
Show all financial metrics

Wave Life Sciences Operating Metrics

FY, 2016

Patents Issued

27

Patents Pending

22

Phase I Trials Products

20

Phase II Trials Products

3
Show all operating metrics

Wave Life Sciences Online and Social Media Presence

Embed Graph

Wave Life Sciences News and Updates

Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington’s Disease

WVE-120102 demonstrates statistically significant reduction in disease-causing mutant HTT protein in CSF vs. placebo

Asuragen Partners with Wave Life Sciences to Develop Companion Diagnostics for Huntingtons Disease

Austin, Texas — 11/25/2019 — Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, and Wave Life Sciences, a clinical-stage genetic medicines company developing life-changing treatments for people battling devastating diseases, …

Wave Life Sciences Announces Fast Track Designation from U.S. FDA for Suvodirsen

Suvodirsen is an investigational stereopure oligonucleotide in development for the treatment of DMD patients amenable to exon 51 skipping

Wave Life Sciences Expands Board of Directors with Three New Appointments

New independent directors bring deep expertise in drug development, commercial operations and government affairs New independent directors bring deep expertise in drug development, commercial operations and government affairs

Wave Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update

Interim efficacy data from ongoing suvodirsen open-label extension study on track for 4Q 2019

Wave Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update

CAMBRIDGE, Mass., May 10, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the first quarter ended March 31, 20…
Show more

Wave Life Sciences Frequently Asked Questions

  • When was Wave Life Sciences founded?

    Wave Life Sciences was founded in 2012.

  • Who are Wave Life Sciences key executives?

    Wave Life Sciences's key executives are Paul Bolno, Chandra Vargeese and Chris Francis.

  • How many employees does Wave Life Sciences have?

    Wave Life Sciences has 250 employees.

  • What is Wave Life Sciences revenue?

    Latest Wave Life Sciences annual revenue is $14.4 m.

  • What is Wave Life Sciences revenue per employee?

    Latest Wave Life Sciences revenue per employee is $57.7 k.

  • Who are Wave Life Sciences competitors?

    Competitors of Wave Life Sciences include Dicerna Pharmaceuticals, LAM Therapeutics and Vivet Therapeutics.

  • Where is Wave Life Sciences headquarters?

    Wave Life Sciences headquarters is located at 733 Concord Ave, Cambridge.

  • Where are Wave Life Sciences offices?

    Wave Life Sciences has offices in Cambridge, Lexington, Dublin 1, Kagoshima and in 2 other locations.

  • How many offices does Wave Life Sciences have?

    Wave Life Sciences has 6 offices.